Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 672 entries
View as:

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01726517 Org: User:
Start: 10/31/12 End: 01/31/14 Due: 01/31/15

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT01334203 Org: User:
Start: 05/31/11 End: 12/31/12 Due: 12/31/13

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Phase: N/A Priority: Normal
NCT ID: NCT01659255 Org: User:
Start: 08/17/12 End: 01/11/16 Due: 01/11/17

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02873936 Org: User:
Start: 07/27/16 End: 06/26/18 Due: 06/26/19

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00389675 Org: User:
Start: 05/31/07 End: 05/31/10 Due: 05/31/11

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Phase: N/A Priority: Normal
NCT ID: NCT01641822 Org: User:
Start: 12/31/12 End: 01/31/15 Due: 01/31/16

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01732913 Org: User:
Start: 01/16/13 End: 05/18/16 Due: 05/18/17

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01605318 Org: User:
Start: 02/12/13 End: 01/03/17 Due: 01/03/18

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Phase: N/A Priority: Normal
NCT ID: NCT01356160 Org: User:
Start: 07/31/11 End: 06/30/13 Due: 06/30/14

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Phase: N/A Priority: Normal
NCT ID: NCT03960645 Org: User:
Start: 06/28/19 End: 08/18/22 Due: 08/18/23

Safety Study of Tecadenoson to Treat Atrial Fibrillation

Phase: N/A Priority: Normal
NCT ID: NCT00713401 Org: User:
Start: 02/29/08 End: 07/31/08 Due: 07/31/09

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Phase: N/A Priority: Normal
NCT ID: NCT02254421 Org: User:
Start: 01/31/15 End: 04/17/17 Due: 04/17/18

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Phase: N/A Priority: Normal
NCT ID: NCT01059565 Org: User:
Start: 02/28/10 End: 01/31/12 Due: 01/31/13

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04854499 Org: User:
Start: 09/07/21 End: 10/02/24 Due: 10/02/25

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05840211 Org: User:
Start: 05/08/23 End: 12/31/28 Due: 12/31/29

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02603107 Org: User:
Start: 11/20/15 End: 12/23/19 Due: 12/23/20

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01847391 Org: User:
Start: 05/31/13 End: 11/30/13 Due: 11/30/14

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT02738333 Org: User:
Start: 04/12/16 End: 05/11/17 Due: 05/11/18

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT03022981 Org: User:
Start: 01/26/17 End: 02/26/20 Due: 02/26/21

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Phase: N/A Priority: Normal
NCT ID: NCT00499720 Org: User:
Start: - End: - Due: -

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Phase: N/A Priority: Normal
NCT ID: NCT00547066 Org: User:
Start: 11/30/07 End: 11/30/11 Due: 11/30/12

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT05770895 Org: User:
Start: 04/03/23 End: 01/15/25 Due: 01/15/26

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT04971785 Org: User:
Start: 08/09/21 End: 12/09/24 Due: 12/09/25

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04115839 Org: User:
Start: 11/13/19 End: 03/18/21 Due: 03/18/22

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03100942 Org: User:
Start: 05/01/17 End: 10/02/19 Due: 10/02/20